Literature DB >> 27995413

Is cytochrome P450 3A4 regulated by menstrual cycle hormones in control endometrium and endometriosis?

Carla A Piccinato1,2, Rosa M Neme3,4, Natália Torres3, Renata Silvério3, Vanessa Bitencourt Pazzini3, Júlio C Rosa E Silva5, Rui A Ferriani5.   

Abstract

The estrogen-metabolizing activities of cytochrome P450 (CYP) enzymes have been implicated in endometriosis. However, their regulation in various sources of endometrial tissue under different hormonal conditions has not been clarified. Our objective was to study the hormone regulation of a specific CYP enzyme, namely CYP3A4, in control (n = 15) and endometriosis patients (n = 42). To this end, we evaluated mRNA expression (using real-time PCR) of CYP3A4 in tissue samples classified according to the phase of menstrual cycle at which they were obtained as confirmed by the related circulating hormone levels. Protein expression was also evaluated by Western Blot. In order to further investigate the hormonal regulation of CYP3A4, stromal cells from ovarian endometriotic lesions were cultured with the prevailing hormones of the distinct phases of the menstrual cycle. We observed that all control and endometriosis tissues express CYP3A4. Nevertheless, changes in CYP3A4 gene expression related to cycle phase were only seen in the control eutopic endometrium and not in samples from endometriosis patients, with an increase in the luteal phase. Stromal cells isolated from ovarian endometriotic lesions expressed CYP3A4 and their exposure to luteal phase-mimicking hormones (estradiol + progesterone) reduced CYP3A4 mRNA in parallel with a diminished expression of the corresponding receptors, estrogen receptor alpha and progesterone receptor. Our findings suggest that steroid hormones are able to regulate CYP3A4 mRNA expression, although the circulating levels of these hormones can only regulate control endometrium and not endometriosis tissues, probably because of dysregulated local steroid concentration in these latter samples.

Entities:  

Keywords:  CYP3A4; Cytochrome P450; Endometriosis; Estrogen metabolism; Estrogen-metabolizing enzymes

Mesh:

Substances:

Year:  2016        PMID: 27995413     DOI: 10.1007/s11010-016-2899-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.

Authors:  H Yamazaki; T Shimada
Journal:  Arch Biochem Biophys       Date:  1997-10-01       Impact factor: 4.013

3.  Endometrial cells from women with endometriosis have increased adhesion and proliferative capacity in response to extracellular matrix components: towards a mechanistic model for endometriosis progression.

Authors:  Petra A B Klemmt; Janet G Carver; Philippe Koninckx; Enda J McVeigh; Helen J Mardon
Journal:  Hum Reprod       Date:  2007-10-05       Impact factor: 6.918

4.  Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: a source of excessive hydroxy-estrogens and ROS?

Authors:  Neli Hevir; Martina Ribič-Pucelj; Tea Lanišnik Rižner
Journal:  Mol Cell Endocrinol       Date:  2012-12-28       Impact factor: 4.102

5.  Effect of TCDD exposure on CYP1A1 and CYP1B1 expression in explant cultures of human endometrium.

Authors:  D P Bofinger; L Feng; L H Chi; J Love; F D Stephen; T R Sutter; K G Osteen; T G Costich; R E Batt; S T Koury; J R Olson
Journal:  Toxicol Sci       Date:  2001-08       Impact factor: 4.849

Review 6.  Progesterone resistance in endometriosis: link to failure to metabolize estradiol.

Authors:  Serdar E Bulun; You-Hong Cheng; Ping Yin; Gonca Imir; Hiroki Utsunomiya; Erkut Attar; Joy Innes; J Julie Kim
Journal:  Mol Cell Endocrinol       Date:  2006-01-10       Impact factor: 4.102

7.  Prosubstrates of CYP3A4, the major human hepatic cytochrome P450: transformation into substrates by other P450 isoforms.

Authors:  D M Stresser; D Kupfer
Journal:  Biochem Pharmacol       Date:  1998-06-01       Impact factor: 5.858

Review 8.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

9.  Elevated expression of CYP1A1 and gamma-SYNUCLEIN in human ectopic (ovarian) endometriosis compared with eutopic endometrium.

Authors:  Maneesh N Singh; Helen F Stringfellow; Siân E Taylor; Kate M Ashton; Mushfika Ahmad; Khalil R Abdo; Omar M A El-Agnaf; Pierre L Martin-Hirsch; Francis L Martin
Journal:  Mol Hum Reprod       Date:  2008-10-10       Impact factor: 4.025

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  3 in total

1.  Site-Specific Regulation of Sulfatase and Aromatase Pathways for Estrogen Production in Endometriosis.

Authors:  Katiane de Almeida Da Costa; Helena Malvezzi; Cristine Dobo; Rosa Maria Neme; Renée Zon Filippi; Thiago Pinheiro Arrais Aloia; Elisa Rampazo Prado; Juliana Meola; Carla de Azevedo Piccinato
Journal:  Front Mol Biosci       Date:  2022-05-03

2.  Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Authors:  Helena Bergström; Anna Lindahl; Anna Warnqvist; Ulf Diczfalusy; Lena Ekström; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2021-12

Review 3.  Antipsychotic medication for women with schizophrenia spectrum disorders.

Authors:  Bodyl A Brand; Yudith R A Haveman; Franciska de Beer; Janna N de Boer; Paola Dazzan; Iris E C Sommer
Journal:  Psychol Med       Date:  2021-11-12       Impact factor: 10.592

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.